From: kristoff@NET.BIO.NET (Dave Kristofferson)
Newsgroups: bionet.sci-resources
Subject: NIH Guide, vol. 22, no. 1, pt. 3, 8 January 1993
Date: 8 Jan 93 03:04:18 GMT
Distribution: bionet


$$XID NIHGUIDE 19930108 V22N01 P3O3 ************************************

Letter of Intent Receipt Date:  February 25, 1993
Application Receipt Date:  March 25, 1993

THE REQUEST FOR APPLICATIONS (RFA) ANNOUNCED IN THIS NOTICE CONTAINS
ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION.
POTENTIAL APPLICANTS MAY OBTAIN THE RFA FROM THE CONTACT NAMED IN
INQUIRES, BELOW.

PURPOSE

The Division of Kidney, Urologic, and Hematologic Diseases (DKUHD) of
the National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK) is soliciting R01 grant applications for support of basic and
clinical studies focused on the normal and abnormal function of the
urinary bladder, specifically as it relates to the urinary bladder
disorders of women: interstitial cystitis, urinary tract infections,
and urinary incontinence.

HEALTHY PEOPLE 2000

The Public Health Service is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas. This RFA,
Interstitial Cystitis and Other Bladder Disorders of Women, is
related to the priority area of ciabetes and chronic disabling
conditions.  Potential applicants may obtain a copy of "Healthy
People 2000" (Full Report:  Stock No. 017-001-00474-0) or Healthy
People 2000" (Summary Report:  Stock No. 017-001-00473-1) through the
Superintendent of Documents, Government Printing Office, Washington,
DC 20402-9325 (telephone 202-783-3238).
ELIGIBILITY REQUIREMENTS

Applications may be submitted by domestic and foreign, for-profit and
non-profit organizations, whether public or private, such as
universities, colleges, hospitals, laboratories, units of State and
local governments, and eligible agencies of the Federal Government.
Minority individuals and women are encouraged to submit as Principal
Investigators.

MECHANISM OF SUPPORT

Support of this program will be through the NIH research project
grant (R01). Responsibility for the planning, direction, and
execution of the proposed project will be solely that of the
applicant.  Except as otherwise stated in this announcement, awards
will be administered under  PHS grants policy as stated in the PHS
Grants Policy Statement.  This RFA is a one-time solicitation.
Generally, future unsolicited competing continuation applications
will compete with all investigator-initiated applications and be
reviewed according to the customary peer review procedures.  The
total requested project period for applications submitted in response
to this RFA may not exceed five years. The average size of an award
is anticipated to be about $200,000 per year total cost.  The
majority of applications funded from this RFA will be for the support
of new projects.  The earliest possible award date will be September
30, 1993.

FUNDS AVAILABLE

For FY 1993, $2,500,000 will be committed by the NIDDK to fund
applications submitted in response to this RFA.  It is anticipated
that 10 to 15 awards will be made by the NIDDK.  This funding level
is dependent upon the receipt of a sufficient number of applications
of high scientific merit.  Applicants must limit their requests to
not more than $160,000 direct costs for the initial budget period.
Although this program is provided for in the financial plan of the
NIDDK the award of grants pursuant to this RFA is also contingent
upon the availability of funds for this purpose.

RESEARCH OBJECTIVES

The objective of this announcement is to solicit applications from
basic science and clinical investigators who will develop new
approaches to the study of the urinary bladder and its disorders in
women. Included in the scope of this RFA are basic and clinical
studies on bladder development, basic bladder physiology, studies of
bladder immunology, bladder mucosa, comparative studies with other
organ sytems such as the gut, etc. especially as related to
intersitial cystitis, urinary tract infections and urinary
incontinence.

SPECIAL REQUIREMENTS

Applicants who receive an award through this announcement are
expected to attend a yearly meeting (convened by the NIDDK) of
investigators to discuss progress and exchange research information.
Funds to support the travel to these meetings may be included in the
proposed budget and can be in addition to other proposed travel.  In
order to ensure that patient selection for clinical studies is
uniform, the NIDDK has established Diagnostic Criteria for research
studies on Interstitial Cystitis (IC).  All Grant Applications For
Research On IC that Use Human Subjects Must State That The NIDDK IC
Dignostic criteria For Research Will Be Applied To Patients Selected
For Inclusion In The Research Study. The NIDDK research criteria have
been published in the Journal Of Urology 142(1): 139, 1989 and the
American Journal Of Kidney Diseases 8(4) 353, 1989.  The Diagnostic
Criteria for other urological diseases that which are studied must
also be defined in the research proposal.

LETTER OF INTENT

Prospective applicants are requested, but not required, to submit a
letter of intent to apply to the RFA.  This letter should include the
name, telephone number and mailing address of the Principal
Investigator, the names of other key personnel, and the name of the
applicant institution, and the number and title of this RFA.  Such a
letter of intent is not binding and it will not enter into the review
of any application subsequently submitted, nor is it a necessary
requirement for application.  Letters of intent are requested solely
for planning purposes.  The NIDDK staff will not provide responses to
such letters.  Letters of intent must be received no later than
February 25, 1993 and must be addressed to:

Dr. Robert Hammond
Chief, Review Branch
The National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 605
Bethesda, MD  20892

APPLICATION PROCEDURES

The research grant application form PHS-398 (revised 9/91) is to be
used in applying for these grants.  The form is available from most
institutional offices of sponsered research and from the Office of
Grants Inquiries, Division of Research Grants, National Institutes of
Health, 5333 Westbard Avenue, Room 449, Bethesda, Maryland 20892,
telephone (301) 496-7441.  The RFA label available in the
application form must be affixed to the bottom of the face page.
Failure to use this label could result in delayed processing of the
application such that it may not reach the review committee in time
for review.  In addition, the RFA title and number must be typed on
line 2a of the face page of the application form and check the YES
box.  Submit a signed, typewritten original of the application,
including the Checklist, and three signed, exact photocopies, in one
package to:  Division Of Research Grants National Institutes of
Health Westwood Building, Room 240 5333 Westbard Avenue Bethesda, MD
20892  At time of submission, two additional copies of the
application must also be sent under separate cover to:  Dr. Robert
Hammond Chief, Review Branch The National Institute of Diabetes and
Digestive and Kidney Diseases Westwood Building, Room 605 5333
Westbard Avenue Bethesda, MD  20892  Applications must be received by
March 25, 1993.  If an application is received after that date, it
will be returned to the applicant.  The Division of Research Grants
(DRG) will not accept any application in response to this
announcement that is essentially the same as one currently pending
initial review, unless the applicant withdraws the pending
application.  However, it is allowable to submit the same project as
both an R01 and as a component project of a program project.  The DRG
will not accept any application that is essentially the same as one
already reviewed.  This does not preclude the submission of
substantial revisions of applications previously reviewed.  Such
applications must not only include an introduction addressing the
previous critique but also be responsive to this RFA.

REVIEW CONSIDERATIONS

Upon receipt, applications will be initially reviewed by the DRG for
completeness. Incomplete applications will be returned to the
applicant without further consideration.  Evaluation for
responsiveness to the program requirements and criteria stated in the
RFA is an NIDDK staff function.  If the application is not responsive
to the RFA, the staff will contact the applicant to determine
returned to the applicant, or whether it should be held until the
next regular receipt date and reviewed in competition with all other
applications.  Those applications are complete and responsive will be
evaluated for scientific/technical merit by an appropriate peer
review group convened by the NIDDK. Following this review, the
applications will be given a secondary review by the National
Diabetes and Digestive and Kidney Diseases Advisory Council unless
not recommended for further consideration by the initial review
group.  Review criteria for this RFA are generally the same as those
for unsolicited research grant applications.

INQUIRIES

Written and telephone inquiries concerning this RFA are encouraged.
Direct inquiries regarding programmatic issues and requests for the
RFA to:

Ralph L. Bain, Ph.D.
Deputy Director, Urology Program
The National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 3A-05
Bethesda, MD  20892
Telephone:  (301) 496-7574
FAX:  (301) 402-0223

Inquiries regarding fiscal matters may be directed to:

Ms. Trude McCain
Grants Management Specialist
Division of Extramural Activities
The National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 649
Bethesda, MD  20892
Telephone:  (301) 496-7467

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic
Assistance No. 93.849 (NIDDK).   Awards are made under authorization
of the Public Health Service Act, Title IV, Part A (Public Law
78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and
administered under PHS grants policies and Federal Regulations 42 CFR
52 and 45 CFR Part 74.  This program is not subject to the
intergovernmental review requirements of Executive Order 12372 or
Health Systems Agency review.

$$R17 END ***********************************************************

$$R18 BEGIN CA-93-16 FULL-TEXT **************************************

SPORE IN GASTROINTESTINAL CANCER

NIH GUIDE, Volume 22, Number 1, January 8, 1993

RFA AVAILABLE:  CA-93-16

P.T. 34; K.W. 0715035, 0705025, 0715085, 0785035, 0795003

National Cancer Institute

Letter of Intent Receipt Date:  February 26, 1993
Application Receipt Date:  April 23, 1993

THE REQUEST FOR APPLICATIONS (RFA) ANNOUNCED IN THIS NOTICE CONTAINS
ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION.
POTENTIAL APPLICANTS MAY OBTAIN THE RFA FROM THE CONTACT NAMED IN
INQUIRIES BELOW.

PURPOSE

The Organ Systems Coordinating Branch of the Division of Cancer
Biology, Diagnosis and Centers (DCBDC) at the National Cancer
Institute (NCI) invites grant applications (P50) to establish
Specialized Programs of Research Excellence that focus on human
Gastrointestinal Cancers of highest incidence and mortality.  These
programs will be established at institutions that will make strong
commitments to the organization and conduct of these programs.  Each
Specialized Program of Research Excellence (SPORE) must be dedicated
to translational research which moves basic research findings into
more applied research settings with patients and populations in order
to have the most immediate impact possible on improving cancer
prevention, diagnoses and treatment and on reducing cancer incidence,
mortality and morbidity.  This could include areas such as the
development of new diagnostic and prognostic tests, the conduct of
innovative therapeutic protocols, the development of new primary and
secondary prevention measures, as well as cancer control studies and
studies that encompass rehabilitation and quality-of-life research.
Each SPORE must 1) both address colorectal cancer and mount a
significant effort on pancreatic cancer; 2) represent a collaborative
enterprise between basic and clinical scientists in the
conceptualization and implementation of research projects; 3) develop
and maintain human cancer tissue resources that will benefit
translational research in these cancers; 4) develop extended
collaborations in critical areas of research need with laboratory and
clinical scientists in the parent institution and in other
institutions; and 5) participate with other SPOREs and/or the NCI on
a regular basis to share information, assess scientific progress in
the field and identify new research opportunities for reducing
colorectal and pancreatic cancer incidence and mortality, and for
increasing and improving survival.  Each SPORE must support a mix of
basic and clinical research and focus on human disease.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This RFA,
"Specialized Program of Research Excellence (SPORE) in
Gastrointestinal Cancer" is related to the priority area of cancer.
Potential applicants may obtain a copy of "Healthy People 2000" (Full
Report:  Stock No. 017-001-00474-1) or "Healthy People 2000" (Summary
Report:  Stock No. 017-001-00473-1) through the Superintendent of
Documents, Government Printing Office, Washington, D. C. 20402-9325
(telephone 202-783-3238).

ELIGIBILITY REQUIREMENTS

Domestic non-profit and for-profit organizations, institutions and
government agencies are eligible to apply.  To be eligible, applicant
organizations must have (1) a minimum of three independent
investigators who are successful in obtaining peer-reviewed research
support directly related to gastrointestinal cancer, and who
represent experience in both laboratory and clinical research.  An
alternative is a minimum of three independent investigators each
having published articles that significantly address gastrointestinal
cancers in peer-reviewed research journals and who combined represent
experience in both laboratory and clinical research; (2) access to a
patient care and service facility that serves gastrointestinal cancer
patients and, if the facility is not part of the parent institution,
a statement signed by the responsible officials of the applicant
institution and the consortial care facility that assures access to
gastrointestinal cancer patients for clinical research.  While
applications must be submitted from a single institution, they may
include consortial arrangements with several institutions as long as
these arrangements are clearly delineated, and formally and
officially confirmed by signed statements from the responsible
officials of each institution.

MECHANISM OF SUPPORT

Support of this program will be through the P50 Specialized Center
Grant mechanism.  This mechanism supports any part of the full range
of research and development from basic to clinical and intervention
studies.  The spectrum of activities comprises a multidisciplinary
attack on a specific disease entity or biomedical problem.  These
grants differ from program project grants in that they are more
complex and flexible in terms of the activities that can be
supported.  In addition to support for multidisciplinary research
projects, support is also provided for pilot research projects,
specialized resources and shared core facilities.  Applicants will be
responsible for the planning, direction, and execution of the
proposed SPORE program.  Awards will be administered under PHS grants
policy as stated in the Public Health Service Grants Policy
Statement, DHHS Publication No. (OASH) 90-50,000 revised October 1,
1990.

This RFA is a one-time solicitation.  The total project period for
applications submitted in response to the present RFA may not exceed
three years.  The anticipated award date will be September 30, 1993.

FUNDS AVAILABLE

This RFA is a one-time solicitation.  NCI anticipates making one or
two awards for initial project periods of three years and anticipates
that a total of $1.5 million will be set aside for the initial year's
funding.  Applicants may apply for part or all of the $1.5 million.
High quality applications that are not fundable in FY 1993 may be
considered for funding in FY 1994.  Funding in response to this RFA
is dependent upon the receipt of a sufficient number of applications
of high scientific merit.  Although this program is provided for in
the financial plans of NCI, the award of grants pursuant to this RFA
is contingent upon the anticipated availability of funds for this
purpose.

RESEARCH OBJECTIVES

The goal of this RFA is to establish SPOREs, which will assemble
critical masses of laboratory and clinical scientists working
together to focus on human gastrointestinal cancers of highest
incidence and the translation of basic findings into applied,
innovative research with patients and populations.  The SPORE must
address both colorectal cancer and pancreatic cancer with a
significant effort directed toward each of these cancers. Of interest
are studies that address black/white differences in incidence and
mortality.  The ultimate objective is to reduce incidence and
mortality, and to increase and improve survival to the disease.  The
essential characteristics of a SPORE include (1) a strong scientific
program which will have a clear impact on the disease, (2) a strong
innovative pilot research program which can respond quickly to new
research opportunities, (3) a human colorectal and pancreatic cancer
tissue procurement resource and other resources specifically
dedicated to translational research objectives.

STUDY POPULATIONS - SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND
MINORITIES IN CLINICAL RESEARCH STUDIES

For projects involving clinical research, NIH requires applicants to
give special attention to the inclusion of women and minorities in
study populations.  If women or minorities are not included in the
study populations for clinical studies, a specific justification for
this exclusion must be provided.  Applications without such
documentation will not be accepted for review.

LETTER OF INTENT

Prospective applicants are asked to submit by February 26, 1993, a
letter of intent that includes the name and address of the Principal
Investigator and identifies the component research projects, core
units and their Principal Investigators, any collaborating
institutions, and the number and title of the RFA in response to
which the application is being submitted.  Although a letter of
intent is not required, is not binding and does not enter into the
review of subsequent applications, it provides an indication of the
number and scope of the applications to be reviewed.  The letter of
intent is sent to Dr. Andrew Chiarodo, whose address is below.

APPLICATION PROCEDURES

Applications must be received by April 23, 1993.  If an application
is received after that date, it will be returned to the applicant
without review.  The Division of Research Grants will not accept any
application in response to this announcement that is essentially the
same as one currently pending initial review, unless the applicant
withdraws the pending application.  The regular research grant
application form PHS 398 (rev. 9/91) must be used in applying for
these grants.  These forms are available at most institutional
offices of sponsored research or from:  Office of Grants Inquiries,
Division of Research Grants, Room 449, Westwood Building,  National
Institutes of Health, Bethesda, MD 20892-4500, Tel:  (301) 496-7441.

Specific instructions for preparing a SPORE grant application are
available as a separate addendum available from the Organ Systems
Coordinating Branch (see below, INQUIRIES).  These instructions
should be used in preparing the application.

REVIEW CONSIDERATIONS

Upon receipt, applications will be initially reviewed for
completeness by the DRG and for responsiveness by the NCI. Incomplete
or non-responsive applications will be returned to the applicant
without further consideration.  Review criteria for RFAs are
generally the same as those for unsolicited research grant
applications.  In addition to rating the merit of individual
components, peer reviewers will be asked to judge the overall program
in the following areas:  scientific merit and innovativeness;
evidence of interdependent, multidisciplinary design and conduct of
the research; potential for impacting on the disease; institutional
commitment.

AWARD CRITERIA

The anticipated date of award is September 30, 1993.  In addition to
the required elements as described above under Special Requirements,
the NCI will consider how well the applicant institutions meet the
goals and objectives of the program as described in the RFA,
availability of resources, and study populations.
INQUIRIES

Written and telephone requests for the RFA and the opportunity to
clarify any issues or questions from potential applicants are
welcome.  Direct requests for the RFA and inquiries regarding
programmatic issues to:

Andrew Chiarodo, Ph.D.
Chief, Organ Systems Coordinating Branch
Executive Plaza North, Suite 512
National Cancer Institute
Bethesda, MD 20892
Telephone:  (301) 496-8528
FAX:  (301) 402-0181

Direct inquiries regarding fiscal matters to:

Robert E. Hawkins
Grants Management Specialist
Executive Plaza South, Room 216
National Cancer Institute
Bethesda, MD 20892
Telephone:  (301) 496-7800, ext. 13

AUTHORITY AND REGULATIONS

This program is described in the catalog of Federal Domestic
Assistance no. 13.397.  Awards are under authorization of the Public
Health Service Act, Title IV, Part A (Public Law 78-410 as amended:
42 USC 241) and administered under PHS grant policies and Federal
Regulations 42 CFR Part 52 and 45 CFR Part 74.  This program is not
subject to the intergovernmental review requirements of Executive
Order 12372 or Health Systems Agency review.

$$R18 END ***********************************************************

$$R19 BEGIN DK-93-15 FULL-TEXT **************************************

PATHOGENESIS OF INFLAMMATORY BOWEL DISEASE AND CELIAC DISEASE

NIH GUIDE, Volume 22, Issue 1, January 8, 1993

RFA AVAILABLE:  DK-93-15

P.T. 34; K.W. 0715085, 0710070, 1002019, 1002004, 1002008, 0785055

National Institute of Diabetes and Digestive and Kidney Diseases

Letter of Intent Receipt Date:  February 26, 1993
Application Receipt Date:       April 21, 1993

THE REQUEST FOR APPLICATIONS (RFA) ANNOUNCED IN THIS NOTICE CONTAINS
ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION.
POTENTIAL APPLICANTS MAY OBTAIN THE RFA FROM THE CONTACT NAMED IN
INQUIRES, BELOW.

PURPOSE

This Request for Applications (RFA) invites new as well as
experienced investigators working in the areas of gastroenterology,
epidemiology, immunology, physiology, molecular and cell biology and
genetics to submit research project grant applications in the area of
autoimmune gastrointestinal diseases including ulcerative colitis,
Crohn's disease and celiac disease. Applications are encouraged from
any interested, especially new investigators, regardless of their
prior record of grant support.

HEALTHY PEOPLE 2000

The PHS is committed to achieving the health promotion and disease
prevention objectives of "Healthy People 2000," a PHS-led national
activity for setting priority areas.  This RFA, Pathogenesis of
Inflammatory Bowel Disease is related to the priority area of
Diabetes and Chronic Disabling Conditions.  Potential applicants may
obtain a copy of "Healthy People 2000" (Full Report: Stock No.
017-001-00474-0) or Healthy People 2000" (Summary Report:  Stock No.
017-001-00473-1) through the Superintendent of Documents, Government
Printing Office, Washington, D.C.  20402-9325 (telephone
202-783-3238).

ELIGIBILITY REQUIREMENTS

Applications may be submitted by domestic and foreign, for-profit or
nonprofit organizations, whether public or private, such as
universities, colleges, hospitals, laboratories, units of State or
local governments, and eligible agencies of the Federal Government.
Minority individuals and women are encouraged to submit as Principal
Investigators.  Foreign institutions are not eligible for FIRST
awards.

MECHANISM OF SUPPORT

The support mechanisms for this research will be the individual
research grant (RO1) and the First Independent Research Support and
Transition (FIRST) Award R29.  This is a one-time solicitation.
Subsequent unsolicited competing continuation applications will
compete with all investigator-initiated applications and will be
reviewed according to customary peer review procedures.  This RFA
will provide the opportunity for investigators to establish support
for periods up to five years for meritorious research projects
designed to investigate the cause, natural history and treatment of
Inflammatory Bowel Disease (IBD) and celiac disease.  This RFA is
intended to support primarily new applications; however, applications
for continuation of currently funded projects will be considered if
they meet the objectives of this RFA.  R01 awards are expected to
average approximately $200,000 per year in total costs.

FUNDS AVAILABLE

For FY 1993, $ 2,000,000 (direct plus indirect costs) will be
committed to fund applications submitted in response to this RFA.  It
is anticipated that 10 to 12 awards will be made depending upon the
receipt of a sufficient number of applications of high scientific
merit.  Applicants must limit their requests to not more than
$160,000 direct costs for the initial budget period.  Although this
program is provided for in the financial plans of the NIDDK, the
award of grants pursuant to this RFA is also contingent upon the
availability of funds for this purpose.

RESEARCH OBJECTIVES

Research objectives of this RFA should focus on but are not limited
to:

o  the role of the mucosal immune system and its immunoregulation in
gastrointestinal inflammation characteristic of IBD and celiac
disease.

o  the role and status of inflammatory mediators, the cytokine system
and adhesion molecules in IBD and celiac disease.

o  the nature of the autoimmune reactions characteristic of IBD and
celiac disease including definition of the autoantigens and the fine
specificity of autoantibodies that are detected in patients with IBD
and celiac disease.

o  genetic markers and specific  gene products associated with IBD
and celiac disease and in particular the molecular genetics of the
major histocompatibility complex in these disorders.

o  epithelial cell biology and its disturbance in gastrointestinal
inflammation characteristic of IBD and celiac disease.

o  the role of luminal bacterial flora viral infections in IBD and
celiac disease.

o  the epidemiology of IBD and celiac disease with particular
attention to special populations and risk factors for development of
these diseases as well as their complications such as sclerosing
cholangitis in ulcerative colitis and lymphoma in celiac disease.

STUDY POPULATIONS

It is NIH policy that women and minorities must be included in
clinical study populations unless there is a good reason to exclude
them, and the study design must seek to identify any pertinent gender
or minority population differences.  If women or minorities are not
included in the study populations for clinical studies, a specific
justification for this exclusion must be provided.  Applications
without such documentation will not be accepted for review.

LETTER OF INTENT

Prospective applicants are asked to submit a letter of intent that
includes a descriptive title of the proposed research, the name,
address, and telephone number of the Principal Investigator, the
identities of other key personnel and participating institutions, and
the number and title of the RFA in response to which the application
is being submitted.  Although a letter of intent is not required, is
not binding, and does not enter into the review of subsequent
applications, the information that it contains is helpful in planning
for the review of applications.  It allows NIDDK staff to estimate
the potential review workload and to avoid possible conflict of
interest in the review.  The letter of intent is to be sent by
February 26, 1993 to:

Robert Hammond, Ph.D., Chief, Review Branch, NIDDK
Westwood Building, Room 605
National Institutes of Health
Bethesda, MD 20892              / Tel:  (301) 496-7083; FAX:  (301)
402-1277

APPLICATION PROCEDURES

The research grant application form PHS-398 (rev. 9/91) must be used
in applying for these grants.  The form is available from most
institutional offices of sponsored research or from the Office of
Grants Inquiries, Division of Research Grants, National Institutes of
Health, 5333 Westbard Avenue, Room 449, Bethesda, Maryland 20892;
(301) 496-7441.  Information describing the FIRST Award grant may
also be obtained from these sources.  The RFA label available in the
9/91 revision of PHS 398 application form must be affixed to the
bottom of the face page.  Additional, detailed instructions on
submission procedures are described the RFA.

Applications must be received by April 21, 1993.  Submit a signed,
typewritten original of the application, including the Checklist, and
three (3) signed, exact photocopies, in one package to:

DIVISION OF RESEARCH GRANTS
National Institutes of Health
Westwood Building, Room 240
Bethesda, Maryland 20892

At the time of submission, two (2) additional copies of the
application should also be sent under separate cover to:

Robert Hammond, Ph.D.
Westwood Building, Room 605
National Institutes of Health
Bethesda, MD  20892

REVIEW CONSIDERATIONS

Applications that are complete and responsive to the RFA will be
evaluated by an appropriate peer review group convened by the NIDDK
in accordance with the usual NIH peer review procedures.  Following
review, the applications will be given a secondary review by the
National Diabetes and Digestive and Kidney Diseases Advisory Council
unless not recommended for further consideration by the initial
review group.  Applications that are incomplete or unresponsive to
the RFA will be returned to the applicant or held until the next
regular receipt date and reviewed by the Division of Research Grants.

INQUIRIES

Written and telephone inquiries concerning this RFA are encouraged.
Inquiries regarding programmatic issues and requests for copies of
the full text RFA should be directed to:

Frank A. Hamilton, M.D., MPH
Westwood Building, Room 3A16
Bethesda, MD 20892
Telephone (301) 496-7821

Inquiries regarding fiscal matters should be directed to:

Mrs. Thelma Jones
Grants Management Specialist, NIDDK
Westwood Bldg. Room 649C
National Institutes of Health
Bethesda, MD 20892
Telephone:  (301) 496-7467

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic
Assistance No. 93.848.  Awards are under authorization of the Public
Health Service Act, Title IV, Part A (Public Law 78-410, as amended
by Public Law 99-158, 42 USC 241 and 285) and administered under PHS
grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74.
This program is not subject to the intergovernmental review
requirements of Executive Order 12372 or Health Systems Agency
review.

$$R19 END ***********************************************************

                    ONGOING PROGRAM ANNOUNCEMENTS

$$P1 BEGIN PA-93-034 ************************************************

MUCOSAL IMMUNITY IN THE UROGENITAL TRACT

NIH GUIDE, Volume 22, Number 1, January 8, 1993

PA NUMBER:  PA-93-034

P.T. 34; K.W. 0705075, 0710070

National Institute of Allergy and Infectious Diseases
National Institute on Aging
National Institute of Child Health and Human Development
National Institute of Diabetes and Digestive and Kidney Diseases

The Division of Allergy, Immunology and Transplantation (DAIT) and
the Division of Microbiology and Infectious Diseases (DMID) of the
National Institutes of Allergy and Infectious Diseases (NIAID); the
National Institute on Aging (NIA); the National Institute of Child
Health and Human Development (NICHD); and the National Institute of
Diabetes and Digestive and Kidney Diseases (NIDDK) invite research
project grant applications for support of basic and preclinical
studies aimed at elucidating the normal and pathologic cellular and
humoral immune responses in the urogenital tract.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This Program
Announcement (PA), Mucosal Immunity in the Urogenital Tract, is
related to the priority area of sexually transmitted diseases,
maternal and infant health, immunization and infectious diseases, and
diabetes and chronic disabling diseases.  Potential applicants may
obtain a copy of "Healthy People 2000" (Full Report:  Stock No.
017-001-00474-0) or "Healthy  People 2000" (Summary Report:  Stock
No. 017-001-00473-1) through the Superintendent of Documents,
Government Printing Office, Washington, DC 20402-0325 (telephone
202-783-3238).

ELIGIBILITY REQUIREMENTS

Research grant applications may be submitted by domestic and foreign,
for-profit and non-profit organizations, public and private, such as
universities, colleges, hospitals, laboratories, units of State and
local governments, and eligible agencies of the Federal government.
Applications from minority individuals and women are encouraged.
Foreign institutions are not eligible to apply for the First
Investigator Research Support and Transition (FIRST) (R29) award.

MECHANISM OF SUPPORT

The mechanism of support will be the individual research project
grant (R01) and the FIRST (R29) award.  Multidisciplinary approaches
that involve collaborative efforts among investigators in the fields
of basic immunology, endocrinology, urology and gynecology are
strongly encouraged.

Policies that govern research grant programs of the National
Institutes of
Health (NIH) will prevail.

RESEARCH OBJECTIVES

Background

Although considerable progress has been made in understanding the
immune responses in mucosal surfaces of the airways and the digestive
tract, there is a serious lack of information regarding the immune
responses in the mucosal lining of the urogenital system.  Recent
technologic advances should make it possible to isolate and
characterize both the cells and the molecules that participate in the
maintenance of immune homeostasis in the genitourinary tract.

Millions of women and men of all ages suffer urinary and genital
infections that not only cause pain, but could also have unwanted
effects on fertility and urinary function.  Despite control efforts
to prevent the spread of STDs, including human immunodeficiency virus
(HIV) infection, both bacterial and viral STDs remain epidemic in
many areas of the United States.  Although curative therapy is
available for some of these acute infections, many individuals go on
to develop serious complications and chronic disease.  Furthermore,
sexually transmitted infections have also been implicated in
increased risk of HIV transmission.

Unfortunately, except for Hepatitis B, there are no vaccines for
STDs.  STD vaccine development is extremely difficult and complex for
reasons related primarily to (1) the nature of the host-pathogen
relationship and (2) the consequences of co-infection with more than
one sexually transmitted pathogen.  As obligate pathogens of humans,
the etiologic agents of these diseases have evolved to effectively
avoid, subvert, or ignore the immunodominant host response.
Furthermore, the presence of multiple infections in the reproductive
tract is likely to complicate vaccine development as pre-existing
STDs compromise epithelial barriers through tissue fragility,
induction of inflammatory cytokines and the recruitment of target
cells, such as lymphocytes (in the case of HIV), thereby lowering the
infectious dose and compromising vaccine efficacy.

Detailed knowledge of the basic mechanisms that normally participate
in mucosal resistance against these conditions could create new
opportunities for vaccine development and intervention.

Research Objectives and Scope

Areas of interest include:

o  Phenotypic and functional analysis of normal immune cell
components in the urogenital mucosal linings, and changes during
puberty, menopause and post-menopause.

o  Studies on the effects of steroid hormones on the composition and
function of immune cells normally present in the mucosa of the
urogenital tract.

o  Determination of the cellular and molecular factors that induce
and regulate antibody production by mucosal-associated lymphocytes.

o  Effects of different forms of antigen presentation and adjuvants
on the development of local immunity.

o  Mechanisms mediating the relationship between immune responses
developing in the urogenital mucosa and systemic immunity.

o  Identification of critical factors that lead to development of
full or partial protective immunity in the mucosal surfaces of the
urogenital tract.

o  Identification of the kinetic parameters of protective immune
responses and of new means to enhance and prolong protective
immunity.

o  Determination of the molecular basis for the observed differences
between the immune responses of the male and female reproductive
tract and of the influence of reproductive hormones on infectivity
and the host response to infection.

STUDY POPULATIONS

SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH
POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDY POPULATIONS

NIH policy is that applicants for NIH clinical research grants and
cooperative agreements are required to include minorities and women
in study populations so that research findings can be of benefit to
all persons at risk of the disease, disorder or condition under
study; special emphasis must be placed on the need for inclusion of
minorities and women in studies of diseases, disorders and conditions
that disproportionately affect them.  This policy is intended to
apply to males and females of all ages.  If women or minorities are
excluded or inadequately represented in clinical research,
particularly in proposed population-based studies, a clear compelling
rationale must be provided.

The composition of the proposed study population must be described in
terms of gender and racial/ethnic group.  In addition, gender and
racial/ethnic issues should be addressed in developing a research
design and sample size appropriate for the scientific objectives of
the study.  This information must be included in the form PHS 398 in
Sections 1-4 of the Research Plan AND summarized in Section 5, Human
Subjects.  Applicants are urged to assess carefully the feasibility
of including the broadest possible representation of minority groups.
However, NIH recognizes that it may not be feasible or appropriate in
all research projects to include representation of the full array of
United States racial/ethnic minority populations (i.e., Native
Americans (including American Indians or Alaskan Natives),
Asian/Pacific Islanders, Blacks, Hispanics).  The rationale for
studies on single minority population groups must be provided.

For the purpose of this policy, clinical research is defined as human
biomedical and behavioral studies of etiology, epidemiology,
prevention (and preventive strategies), diagnosis, or treatment of
diseases, disorders or conditions, including but not limited to
clinical trials.

The usual NIH policies concerning research on human subjects also
apply.  Basic research or clinical studies in which human tissues
cannot be identified or linked to individuals are excluded.  However,
every effort should be made to include human tissues from women and
racial/ethnic minorities when it is important to apply the results of
the study broadly, and this should be addressed by applicants.

For foreign awards, the policy on inclusion of women applies fully;
since the definition of minority differs in other countries, the
applicant must discuss the relevance of research involving foreign
population groups to the United States' populations, including
minorities.

If the required information is not contained within the application,
the review will be deferred until the information is provided.  Peer
reviewers will address specifically whether the research plan in the
application conforms to these policies.  If the representation of
women or minorities in a study design is inadequate to answer the
scientific question(s) addressed AND the justification for the
selected study population is inadequate, it will be considered a
scientific weakness or deficiency in the study design and will be
reflected in assigning the priority score to the application.

All applications for clinical research submitted to NIH are required
to address these policies.  NIH funding components will not award
grants or cooperative agreements that do not comply with these
policies.

APPLICATION PROCEDURES

Applicants are to use the research grant application form PHS 398
(rev. 9/91).  For purposes of identification and processing, check
yes on item 2a of the face page and enter the title, PA-93-: Mucusal
Immunity in the Genital Tract.  Applications will be accepted in
accordance with the standard submission dates for new applications:
February 1, June 1, and October 1.  All applications will be assigned
by the Division of Research Grants (DRG) for review according to the
NIH process for regular research grant applications.

Applicants from institutions that have a General Clinical Research
Center (GCRC) funded by the NIH National Center for Research
Resources may wish to identify the GCRC as a resource for conducting
the proposed research.  If so, a letter of agreement from either the
GCRC program director or principal investigator could be included
with the application.

Application kits are available at most institutional offices of
sponsored research and may be obtained from the Office of Grants
Inquiries, Division of Research Grants, National Institutes of
Health, Westwood Building, Room 449, Bethesda, MD 20892, telephone
(301) 496-7441.

The completed original application and five legible copies must be
sent or delivered to:

Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892**

REVIEW CONSIDERATIONS

Applications will be assigned on the basis of established PHS
referral guidelines.  Applications will be reviewed for scientific
and technical merit by study sections of the DRG, in accordance with
the standard NIH peer review procedures.  Following
scientific-technical review, the applications will receive a
second-level review by an appropriate national advisory council or
board.

AWARD CRITERIA

Applications will compete for available funds with all other approved
applications.  The following will be considered in making funding
decisions:  quality of the proposed project as determined by peer
review, availability of funds, and program balance among research
areas of the announcement.

INQUIRIES

Requests for additional information and questions regarding this
program may be directed to:

Dr. Susana Serrate-Sztein
Division of Allergy, Immunology and Transplantation
National Institute of Allergy and Infectious Diseases
Solar Building, Room 4A20
Bethesda, MD  20892
Telephone:  (301) 496-7985
FAX:  (301) 402-0175

Dr. Penny Hitchcock
Sexually Transmitted Diseases Branch
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases
Solar Building, Room 3A21
Bethesda, MD  20892
Telephone:  (301) 402-0443
FAX:  (301) 402-1456

Dr. David H. Lavrin
Biology of Aging Program
National Institute on Aging
Gateway Building, Room 2C231
Bethesda, MD  20892
Telephone:  (301) 496-6402

Dr. Michael E. McClure
Reproductive Science Branch, Center for Population Research
National Institute of Child Health and Human Development
Executive Plaza North, Room 603
Bethesda, MD  20892
Telephone:  (301) 496-6515
FAX:  (301) 496-0962

Dr. Leroy M. Nyberg
Division of Kidney, Urologic and Hematologic Disorders
National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 3A-05A
Bethesda, MD  20892
Telephone:  (301) 496-8248

Direct inquiries regarding fiscal matters to:

Mr. Jeffrey Carow
Chief, Immunology Grants Management Section
Division of Extramural Affiars
National Institute of Allergy and Infectious Diseases
Solar Building, Room 4B29
Bethesda, MD  20892
Telephone:  (301) 496-7075

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal
DomesticAssistance, No. 93.855 - Immunology, Allergic and Immunologic
Diseases Research.  Grants are awarded under the authority of the
Public Health Service Act, Section 301 (42 USC 241) and administered
under PHS grants policies and Federal Regulations, most specifically
at 42 CFR Part 52 and 45 CFR Part 74.  This program is not subject to
the intergovernmental review requirements of Executive Order 12372 or
Health Systems Agency review

$$P1 END ************************************************************

$$P2 BEGIN PA-93-035 ************************************************

RESEARCH ON SALIVARY GLANDS AND SECRETIONS

NIH GUIDE, Volume 22, Number 1, January 8, 1993

PA NUMBER:  PA-93-035

P.T. 34; K.W. 0715148, 0785035

National Institute of Dental Research

PURPOSE

The National Institute of Dental Research (NIDR) supports studies to
improve knowledge of the development, structure, function, and
diseases of the salivary glands and to determine the influence of
salivary constituents on oral health.  Toward this end, the NIDR
seeks to enhance its support of basic and clinical research in the
broad area of the salivary system.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This Program
Announcement (PA), Research on Salivary Glands and Secretions, is
related to the priority area of oral health.  Potential applicants
may obtain a copy of "Healthy People 2000" (Full Report:  Stock No.
017-001-00474-0) or "Healthy People 2000" (Summary Report:  Stock No.
017-001-00473-1) through the Superintendent of Documents, Government
Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238).

ELIGIBILITY REQUIREMENTS

Applications may be submitted by domestic and foreign, for-profit and
non-profit organizations, public and private, such as universities,
colleges, hospitals, laboratories, units of State and local
governments, and eligible agencies of the Federal government.
Domestic applications may include international components.  Foreign
institutions are not eligible for the First Independent Research
Support and Transition (FIRST) (R29) award.  Applications from
minority individuals and women are encouraged.  Special eligibility
requirements specified in the pertinent guidelines for the various
mechanisms available for support of this program must be met.

MECHANISMS OF SUPPORT

The mechanisms available for support of this program include the
traditional research project grant (R01), the program project grant
(P01), the First Independent Research Support and Transition (FIRST)
(R29) award, and the small grant (R03).

Because the nature and scope of the research proposed in response to
this PA may vary, it is anticipated that the size of an award will
vary also.

RESEARCH OBJECTIVES

Background

Salivary gland research over the past two decades has been
compartmentalized into two general areas:  (1) salivary secretions
(extracellular events) and (2) salivary glands (intracellular
processes).  Our knowledge of salivary secretions has proceeded at a
faster pace than that of intracellular processes.  Nevertheless,
salivary research is at a crossroads due to the emergence of new
biologies, most notably recombinant technologies, cell biology, and
protein engineering.  Indeed, the future of salivary research will
require the integration of these new disciplines with the more
traditional disciplines.  Salivary researchers are at the critical
threshold of having a large volume of scientific information that can
be applied clinically towards enhancing natural defense mechanisms.
For example, studies in the not-too-distant future could be directed
toward topical vaccines against oral disease, the development of
artificial salivas, or the diagnostic use of sialochemistry by dental
practitioners.  Before these clinical goals can be achieved, however,
additional research is needed regarding the intracellular and
extracellular events that modulate saliva secretion and function.
Finally, clinical applications will demand consideration of normal
vs. the compromised host, normal vs. high-risk populations, and local
vs. systemic diseases in order to develop the appropriate diagnostic
and treatment modalities.

Research Goals and Scope

The NIDR has been a mainstay of support for research and related
training on salivary glands and their secretions and has thus
contributed to advances in basic research and furthered progress in
understanding diseases or syndromes in which salivary gland function
is compromised.  Based on recommendations by the Dental Research
Programs Advisory Committee at its June 7-8, 1988 meeting, the NIDR
"Broadening the Scope:  Long-Range Research Plan for the Nineties,"
and the NIDR-sponsored international conference on "Contemporary
Developments in Salivary Research" organized by Dr. Michael J. Levine
and held on November 6-10, 1991 at Buffalo, New York, the NIDR
desires to enhance its support of both basic and clinical research in
the broad area of this announcement.  Accordingly, applications are
invited for research project grants (including minority research
supplements), program project grants, FIRST awards, and small grants
related, but not limited to, the following areas:

o  Description of the characteristics of the salivary-associated
lymphoid tissue with emphasis on:  (a) the mechanisms of homing of
immune component cells to and within salivary glands, (b) the
cellular elements and factors regulating differentiation and antibody
production within specific gland types, including neuropeptide
modulation of salivary immunity, (c) the intrinsic and extrinsic
factors involved in the ontogeny of salivary immunity, and (d)
specific enhancement of host defenses using local antigen delivery
methods.

o  Definition of the molecular mechanisms involved in salivary
secretion with emphasis on: (a) the diversity of signal transduction
processes present in different salivary tissues and species, (b) the
mechanisms of sorting and packaging of stored proteins into secretory
granules in acinar cells, and (c) the mechanisms of secretory
granule-plasma membrane fusion and its role on the process of
exocytosis.

o  Further definition of the mechanisms of salivary-specific gene
expression in developing and adult glands of various species with
emphasis on:  (a) the trans-acting factors that modulate gene
transcription, and (b) the exogenous factors that modulate gene
expression, thereby enabling genetic manipulation of salivary glands
to address clinical problems.

o  Development of sophisticated model systems (transgenic animals and
immortalized salivary gland epithelial cell lines with appropriate
phenotypic expression) to investigate normal cellular processes and
those evident in disease.

o  Extension of studies of the structure and function of salivary
macromolecules to determine specific functional domains.

o  Confirmation of the biological role of individual salivary
molecules in vivo.

o  Definition of salivary function in acquired immune deficiency
syndrome (AIDS) and clarification of the role of salivary secretions
in preventing oral transmission of human immunodeficiency virus
(HIV).

o  Further research on the use of saliva to diagnose and monitor drug
therapy and abuse, endocrine function, systemic disease, oral health,
genetic defects, nutritional status, and age-specific changes.

o  Further investigations on the epidemiology, etiology,
pathogenesis, diagnosis, and treatment of salivary gland disorders,
such as Sjogren's syndrome.

o  Development of new sialogogues and improved, long-acting saliva
substitutes.

o  Development of methods to expand and improve function of residual
salivary gland tissue after destructive disease or therapy (e.g.,
radiation or chemotherapy to treat head and neck cancers).  This
research should include methods aimed at tissue repair and
regeneration.

o  Development of organoids and techniques for the preservation and
transplantation of salivary glands.

It should be reemphasized that the above list of potential areas of
investigation is not intended to be either comprehensive or
exclusive, nor is it in order of priority. Rather, it is intended to
exemplify the wide variety of new and/or continuing program emphases.

STUDY POPULATIONS

SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH
POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDY POPULATIONS

NIH policy is that applicants for NIH clinical research grants and
cooperative agreements are required to include minorities and women
in study populations so that research findings can be of benefit to
all persons at risk for the disease, disorder or condition under
study; special emphasis must be placed on the need for inclusion of
minorities and women in studies of diseases, disorders and conditions
which disproportionately affect them.  This policy is intended to
apply to males and females of all ages.  If women or minorities are
excluded or inadequately represented in clinical research,
particularly in proposed population-based studies, a clear compelling
rationale must be provided.

The composition of the proposed study population must be described in
terms of gender and racial/ethnic group.  In addition, gender and
racial/ethnic issues should be addressed in developing a research
design and sample size appropriate for the scientific objectives of
the study.  This information must be included in the form PHS 398
(rev. 9/91) in Sections 1-4 of the Research Plan AND summarized in
Section 5, Human Subjects.  Applicants are urged to assess carefully
the feasibility of including the broadest possible representation of
minority groups.  However, NIH recognizes that it may not be feasible
or appropriate in all research projects to include representation of
the full array of United States racial/ethnic minority populations
(i.e., Native Americans [including American Indians or Alaskan
Natives], Asian/Pacific Islanders, Blacks, Hispanics).  The rationale
for studies on single minority population groups should be provided.

For the purpose of this policy, clinical research is defined as human
biomedical and behavioral studies of etiology, epidemiology,
prevention (and preventive strategies), diagnosis, or treatment of
diseases, disorders or conditions, including but not limited to
clinical trials.

The usual NIH policies concerning research on human subjects also
apply.  Basic research or clinical studies in which human tissues
cannot be identified or linked to individuals are excluded.  However,
every effort should be made to include human tissues from women and
racial/ethnic minorities when it is important to apply the results of
the study broadly, and this should be addressed by applicants.

For foreign awards, the policy on inclusion of women applies fully;
since the definition of minority differs in other countries, the
applicant must discuss the relevance of research involving foreign
population groups to the United States' populations, including
minorities.

If the required information is not contained within the application,
the review will be deferred until the information is provided.

Peer reviewers will address specifically whether the research plan in
the application conforms to these policies.  If the representation of
women or minorities in a study design is inadequate to answer the
scientific question(s) addressed AND the justification for the
selected study population is inadequate, it will be considered a
scientific weakness or deficiency in the study design and will be
reflected in assigning the priority score to the application.

All applications for clinical research submitted to NIH are required
to address these policies.  NIH funding components will not award
grants or cooperative agreements that do not comply with these
policies.

APPLICATION PROCEDURES

Applications will be accepted in accordance with the receipt, Initial
Review Group, National Advisory Council, and earliest possible
beginning dates specified in the pertinent application kits.  The
specific application forms and kits required in this connection are
available at most institutional offices of sponsored research and may
be obtained from the Office of Grants Inquiries, Division of Research
Grants, National Institutes of Health, Westwood Building, Room 449,
Bethesda, MD 20892, telephone (301) 496-7441.  The YES box must be
checked and the title, Research on Salivary Glands and Secretions,
and number of the announcement must be typed in Section 2a on the
face page of the application form PHS 398 (rev. 9/91).

FIRST award applications must include at least three sealed letters
of reference attached to the face page of the original application.
FIRST award applications submitted without the required number of
reference letters will be considered incomplete and will be returned
without review.

The completed original application and five legible copies must be
sent or delivered to:

Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892**

REVIEW PROCEDURES

Applications will be assigned on the basis of established PHS
referral guidelines.  Applications will be reviewed for scientific
and technical merit in accordance with standard NIH peer review
procedures and the review criteria customary for the support
mechanism selected.  Following scientific-technical review, the
applications will receive a second-level review by one or more
appropriate national advisory councils or boards.

AWARD CRITERIA

Applications recommended for further consideration will compete for
available funds with all other applications.  The following will be
considered in making funding decisions:  quality of the proposed
project as determined by peer review, availability of funds, and
program balance among research areas of the announcement.  The NIDR
appreciates the value of complementary funding from other public and
private sources, including foundations and industrial concerns, for
activities that will complement and expand those supported by the
NIDR.

INQUIRIES

Written and telephone inquiries are encouraged.  The opportunity to
clarify any issues or questions from potential applicants is welcome.

Direct inquiries regarding programmatic issues to:

G.G. Roussos, Ph.D.
Director, Salivary Research and Oral Biology Centers Program
Extramural Program
National Institute of Dental Research
Westwood Building, Room 509
Bethesda, MD  20892
Telephone:  (301) 496-7784

Direct inquiries regarding fiscal matters to:

Ms. Theresa Ringler
Chief, Grants Management Section
Extramural Program
National Institute of Dental Research
Westwood Building, Room 510
Bethesda, MD  20892
Telephone:  (301) 496-7437

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic
Assistance No. 93.121.  Awards are made under authorization of the
Public Health Service Act, Title IV, Part A (Public Law 78-410, as
amended by Public Law 99-158, 42 USC 241 and 285) and administered
under PHS grants policies and Federal Regulations 42 CFR 52 and 45
CFR Part 74.  This program is not subject to the intergovernmental
review requirements of Executive Order 12372 or Health Systems Agency
review.

$$P2 END ************************************************************

                               ERRATA

$$E1 BEGIN R9 19921211 APPEND RFA AR-93-03 FULL ************************

SKIN DISEASES RESEARCH CORE CENTERS

NIH GUIDE, Volume 22, Number 1, January 8, 1993

RFA:  AR-93-03

P.T. 04; K.W. 0715185, 0710070, 0710031

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Letter of Intent Receipt Date:  May 10, 1993
Application Receipt Date:  June 18, 1993

In the full text of the RFA, under FUNDS AVAILABLE, the first
sentence should read "The NIAMS intends to fund two SDRCs from this
RFA..."  As released, the RFA says three rather than two.  The
correct information was provided in the Notice of Availability of the
RFA.

INQUIRIES

Dr. Michael Lochshin
Director of Extramural Programs
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Telephone:  (301)-496-0802

$$E1 END ************************************************************
Newsgroups: bionet.sci-resources